Τίτλος:
Two cycles of etoposide/cisplatin cured all patients with stage I
testicular seminoma: Risk-adapted protocol of the Hellenic Cooperative
Oncology Group
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
OBJECTIVES Adjuvant carboplatin is used as adjuvant therapy in Stage I
testicular seminoma. Although cure is the rule, relapses still occur,
especially in high-risk populations. We report the results of a
risk-adapted strategy by the Hellenic Cooperative Oncology Group.
METHODS From 1996 to 2003, 64 patients with Stage I seminoma and one of
two risk factors (maximal tumor diameter greater than 4 cm and/or age
younger than 34 years) were prospectively included in a protocol of
adjuvant chemotherapy. Treatment consisted of two 3-week courses of
etoposide 120 mg/m(2) and cisplatin 40 mg/m(2) for three consecutive
days with granulocyte colony-stimulating factor support.
RESULTS Of the 64 patients, 43 (67%) were younger than 34 years and 55
(86%) had a tumor diameter greater than 4 cm. Neutropenia and nausea
and vomiting were the most frequent grade 3 or 4 toxicities (16.5% and
9.5%, respectively), apart from alopecia. After a median follow-up of
60 months (range 7 to 118), no disease relapses have occurred. A
metachronous testicular carcinoma has been reported. One patient died of
causes unrelated to his disease.
CONCLUSIONS The results of our study have shown that two cycles of
etoposide and cisplatin is an effective and safe form of adjuvant
therapy for Stage I testicular seminoma. Risk factors can be used to
identify patients who could benefit from etoposide and cisplatin
treatment.
Συγγραφείς:
Bamias, Aristotelis
Aravantinos, Gerassimos
Deliveliotis,
Charalambos
Thanos, Anastasios
Klouvas, George
Antoniou,
Nikolaos
Poulias, Iraklis
Makatsoris, Thomas
Samantas,
Epaminondas
Dimopoulos, Meletios A.
Περιοδικό:
European urology oncology
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI:
10.1016/j.urology.2007.07.016
